| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Benzylthiouracil targets thyroid peroxidase (TPO), the enzyme responsible for the iodination of tyrosine residues and coupling of iodotyrosines in thyroid hormone synthesis. By inhibiting TPO, it blocks the production of thyroid hormones thyroxine (T4) and triiodothyronine (T3). The compound's thioamide group is essential for its antithyroid activity. The benzyl substitution at the 6-position confers distinct binding characteristics and biological activity that vary across experimental models. The compound's enhanced lipophilicity (AlogP ~1.6-2.0) may affect its tissue distribution and pharmacokinetic properties.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that Benzylthiouracil acts as a thyroid peroxidase inhibitor, blocking the iodination of tyrosine residues and coupling of iodotyrosines. The 6-benzyl substitution confers distinct binding characteristics and biological activity. The compound's antithyroid activity has been characterized in various in vitro systems. Its ability to induce ANCA-associated glomerulonephritis has been observed. These in vitro findings support its applications in thyroid research and hyperthyroidism studies.
|
| ln Vivo |
In vivo studies have demonstrated that Benzylthiouracil is ten times more potent than thiouracil and methylthiouracil in inhibiting the thyroid's ability to naturally collect iodine in rats. However, there was no significant difference in the duration of inhibition at the smallest effective dose. The compound induces ANCA-associated glomerulonephritis in Graves' disease patients. It is used to study hyperthyroidism. These in vivo findings support its utility as a research tool for studying thyroid function and autoimmune diseases.
|
| Enzyme Assay |
In vitro enzyme assays for Benzylthiouracil typically involve testing its inhibitory activity against thyroid peroxidase (TPO). Enzyme activity is measured by monitoring the iodination of tyrosine residues or the formation of iodothyronines in the presence of varying concentrations of the compound. IC50 values are determined from dose-response curves. The compound's purity and identity are assessed using analytical chemistry methods such as nuclear magnetic resonance spectroscopy, high-performance liquid chromatography, and mass spectrometry. All assays are performed with appropriate controls and standardized protocols to ensure reproducibility of results.
|
| Cell Assay |
In vitro cell-based assays for Benzylthiouracil involve culturing thyroid cells to evaluate its effects on thyroid hormone synthesis. Cells are treated with varying concentrations of the compound and thyroid hormone production is measured by ELISA or radioimmunoassay. For ANCA-associated glomerulonephritis studies, immune cells are treated and ANCA production is assessed. Cell viability is assessed using MTT or similar colorimetric assays to ensure that observed effects are not due to cytotoxicity. All experiments are performed in triplicate with appropriate controls to ensure statistical reliability.
|
| Animal Protocol |
In vivo animal experiments for Benzylthiouracil utilize rodent models to evaluate its antithyroid activity. Rats are administered the compound and thyroid iodine uptake is measured. The compound was observed to be ten times more potent than thiouracil and methylthiouracil in inhibiting the thyroid's ability to naturally collect iodine. Parameters assessed include thyroid hormone levels, iodine uptake, and thyroid histopathology. For ANCA-associated glomerulonephritis studies, animal models of autoimmune disease are used. Control groups receiving vehicle alone are included for comparison. All procedures comply with institutional animal care and use committee guidelines.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Benzylthiouracil reflect its nature as a thioamide-class antithyroid agent. It has a molecular weight of 218.27 and the molecular formula C11H10N2OS. The benzyl substitution at the 6-position imparts enhanced lipophilicity (AlogP ~1.6-2.0) and altered pharmacokinetic properties relative to other thiouracil derivatives. The compound is soluble in DMSO at 180 mg/mL (824.63 mM). It is stored at low temperature, away from moisture. Complete pharmacokinetic profiling including half-life, clearance, volume of distribution, and bioavailability would require further systematic studies.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Benzylthiouracil has been evaluated in the context of its use as a research chemical and antithyroid agent. The compound induces ANCA-associated glomerulonephritis in Graves' disease patients. It is used to study hyperthyroidism. As a thioamide-class compound, it may have adverse effects similar to other antithyroid agents. Proper handling procedures including use of personal protective equipment are recommended when working with pure compound. The compound is not approved for human therapeutic use and is intended for research purposes only. Long-term toxicity studies would be needed to fully establish its safety profile.
|
| References | |
| Additional Infomation |
Benzylthiouracil is a pyrimidinone.
Benzylthiouracil (CAS# 6336-50-1) is also known as 6-Benzyl-2-thiouracil. It has the molecular formula C11H10N2OS and a molecular weight of 218.27. The compound is a thioamide-class antithyroid agent that acts as a thyroid peroxidase inhibitor. It blocks the iodination of tyrosine residues and coupling of iodotyrosines essential for thyroid hormone synthesis. The benzyl substitution at the 6-position imparts enhanced lipophilicity. The compound induces ANCA-associated glomerulonephritis and is used to study hyperthyroidism. In rats, it is ten times more potent than thiouracil in inhibiting iodine uptake. It is intended for research use only. |
| Molecular Formula |
C11H10N2OS
|
|---|---|
| Molecular Weight |
218.27
|
| Exact Mass |
218.051
|
| CAS # |
6336-50-1
|
| PubChem CID |
685814
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.32g/cm3
|
| Boiling Point |
438.1ºC at 760 mmHg
|
| Flash Point |
218.8ºC
|
| Index of Refraction |
1.678
|
| LogP |
2.023
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
15
|
| Complexity |
306
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C=C1)CC2=CC(=O)NC(=S)N2
|
| InChi Key |
PNXBXCRWXNESOV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H10N2OS/c14-10-7-9(12-11(15)13-10)6-8-4-2-1-3-5-8/h1-5,7H,6H2,(H2,12,13,14,15)
|
| Chemical Name |
6-benzyl-2-sulfanylidene-1H-pyrimidin-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 200 mg/mL (916.30 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.5815 mL | 22.9074 mL | 45.8148 mL | |
| 5 mM | 0.9163 mL | 4.5815 mL | 9.1630 mL | |
| 10 mM | 0.4581 mL | 2.2907 mL | 4.5815 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
